Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition; Strengthens Pathway to Low-Cost Customer Acquisition

Rhea-AI Summary

Exousia Pro (OTCID: MAJI) announced a third Letter of Intent to acquire an established telehealth organization as part of a vertical integration strategy in healthcare.

The acquisition aims to provide direct-to-patient distribution for proprietary nutraceuticals and advanced cancer screening tests, reduce customer acquisition cost, and generate performance-based revenue (10% of hospital savings over four years).

Positive

• Third LOI executed to acquire an established telehealth organization
• Access to built-in patient/provider network for direct marketing of clinical products
• Performance-based revenue: target earns 10% of hospital savings over a four-year period
• Front-loaded cash flow: majority of commissions realized within first two years

Negative

• Definitive agreements delayed past original end-of-January target due to extended due diligence
• Current acquisition status is LOI and under review, creating timing and execution uncertainty

ORLANDO, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCID: MAJI), a clinical-stage biotechnology company specializing in proprietary exosome-based delivery systems, is pleased to announce a significant acceleration in its healthcare vertical with the execution of a third Letter of Intent (LOI) to acquire an established telehealth organization.

Strategic Infrastructure & Direct-to-Patient Network

This third acquisition represents a cornerstone in Exousia’s strategy to build a vertically integrated health ecosystem. By acquiring established telehealth platforms, MAJI is not only securing independent revenue streams but is also gaining immediate access to a vast, built-in network of patients and providers.

This internal network serves as a high-efficiency distribution channel for the Company’s:

• Proprietary Nutraceutical Products
• Advanced Cancer Screening Tests

By marketing these high-value clinical products directly through its own telehealth channels, Exousia expects to achieve a drastically lower Customer Acquisition Cost (CAC) compared to traditional industry standards, driving higher margins and accelerated market penetration.

Specialized 3rd Acquisition: Institutional Scale

The latest target organization operates within a prestigious niche, partnering with University-connected hospitals across the United States. This company utilizes a proprietary model that can reduce hospital prescription costs by up to 50%.

The Revenue Model:

• Performance-Based Earnings: The company typically receives 10% of the total savings generated for the hospital over a four-year period.
• Front-Loaded Cash Flow: The majority of commissions are realized within the first two years, followed by recurring residual payments, providing the Company with robust, predictable cash flow.

Due Diligence & Timeline Update

Management is currently finalizing the extensive due diligence process for the initial two acquisitions. While the Company originally aimed to execute definitive agreements by the end of January, the depth of the audit-ready verification process—designed to ensure long-term shareholder value and transparency—has moved the execution date to later this month. Due diligence materials for the third acquisition have already been received and are under active review.

Leadership Perspective

"We are aggressively scaling our healthcare infrastructure through these targeted acquisitions," stated Matt Dwyer, President of Exousia Pro, Inc. "Beyond the significant standalone revenue these entities generate, they provide us with a captive, high-intent audience. This allows us to deliver our cutting-edge cancer screening tests and nutraceuticals directly to patients at a fraction of the usual marketing cost. We are building a self-sustaining cycle of clinical innovation and efficient commercialization."

About Exousia Pro, Inc. Exousia Pro, Inc. is a biotechnology company at the forefront of exosome research, focused on developing next-generation delivery systems for therapeutic and diagnostic applications. Through its expanding telehealth division, the Company aims to bridge the gap between clinical innovation and patient access.

Forward-Looking Statements: This press release contains forward-looking statements regarding the timing of definitive agreements and the expected benefits of acquisitions. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially.

SAFE HARBOR

Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

CONTACT:

Exousia Pro, Inc.
www.Exousiapro.com
X: @Exousia_Pro

Investor Relations
ir@exousiapro.com

FAQ

What did Exousia Pro (MAJI) announce on February 10, 2026 about telehealth acquisitions?

They announced a third Letter of Intent to acquire an established telehealth organization. According to the company, this adds a direct-to-patient network to market nutraceuticals and cancer screening tests, aiming to lower customer acquisition cost and generate performance-based revenue.

How will the MAJI telehealth acquisition affect Exousia Pro's customer acquisition cost?

The acquisition is intended to drastically lower Customer Acquisition Cost by using in-house telehealth channels. According to the company, marketing through the acquired patient/provider network should improve margins and speed market penetration versus traditional marketing methods.

What is the revenue model for the telehealth target in Exousia Pro's third LOI (MAJI)?

Revenue is performance-based, with the target typically receiving 10% of total hospital savings over four years. According to the company, most commissions are front-loaded in the first two years with recurring residual payments thereafter.

What material operational claim did Exousia Pro (MAJI) report about the telehealth partner's impact on hospitals?

The target reportedly can reduce hospital prescription costs by up to 50%. According to the company, that cost-reduction model underpins the performance-based earnings and potential value capture for Exousia Pro.

What is the timeline and current status for Exousia Pro's (MAJI) acquisition agreements?

Definitive agreements were expected by end of January but are delayed to later this month due to extended audit-ready due diligence. According to the company, due diligence for the third acquisition is underway with materials already received.